Using protein therapy to treat heart and lung damage caused by viruses
Protein therapy to treat virus induced cardiopulmonary injury
['FUNDING_R01'] · UNIVERSITY OF VIRGINIA · NIH-11077288
This study is looking at how a protein called MG53 might help heal heart and lung injuries caused by viral infections like the flu, with the goal of reducing inflammation and helping patients recover better.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | UNIVERSITY OF VIRGINIA (nih funded) |
| Locations | 1 site (CHARLOTTESVILLE, UNITED STATES) |
| Trial ID | NIH-11077288 on ClinicalTrials.gov |
What this research studies
This research investigates the use of a protein called MG53 to treat injuries to the heart and lungs caused by viral infections, particularly influenza. The approach focuses on reducing inflammation and promoting tissue repair in patients suffering from virus-induced cardiopulmonary injuries. By administering recombinant human MG53, the study aims to restore normal function in affected organs and improve overall patient outcomes. The research utilizes animal models to explore the effectiveness of this therapy before potential application in humans.
Who could benefit from this research
Good fit: Ideal candidates for this research would include individuals experiencing severe respiratory infections, particularly those with complications affecting heart function.
Not a fit: Patients with non-viral related cardiopulmonary issues or those who do not have significant inflammation may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new treatments that significantly improve recovery from viral infections affecting the heart and lungs.
How similar studies have performed: Previous studies have shown promising results with similar protein therapies in animal models, indicating potential for success in human applications.
Where this research is happening
CHARLOTTESVILLE, UNITED STATES
- UNIVERSITY OF VIRGINIA — CHARLOTTESVILLE, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: MA, JIANJIE — UNIVERSITY OF VIRGINIA
- Study coordinator: MA, JIANJIE
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.